MX2016010057A - Compuestos antibacterianos. - Google Patents
Compuestos antibacterianos.Info
- Publication number
- MX2016010057A MX2016010057A MX2016010057A MX2016010057A MX2016010057A MX 2016010057 A MX2016010057 A MX 2016010057A MX 2016010057 A MX2016010057 A MX 2016010057A MX 2016010057 A MX2016010057 A MX 2016010057A MX 2016010057 A MX2016010057 A MX 2016010057A
- Authority
- MX
- Mexico
- Prior art keywords
- polymyxin
- bacterial infections
- gram
- antibacterial combinations
- antibacterial
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title abstract 2
- 108010040201 Polymyxins Proteins 0.000 title 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 244000000058 gram-negative pathogen Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación se refiere a una combinación novedosa de compuestos, a su uso como agentes antibacterianos, a composiciones que los comprenden y a métodos para tratar o prevenir infecciones bacterianas, más en particular, infecciones bacterianas causadas por patógenos Gram negativos y/o bacterias Gram negativas resistentes a fármacos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014900308A AU2014900308A0 (en) | 2014-02-03 | Antibacterial compounds | |
AU2014902238A AU2014902238A0 (en) | 2014-06-12 | Antibacterial compounds | |
PCT/IB2015/000177 WO2015114452A2 (en) | 2014-02-03 | 2015-02-03 | Antibacterial compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016010057A true MX2016010057A (es) | 2017-04-27 |
Family
ID=52627536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010057A MX2016010057A (es) | 2014-02-03 | 2015-02-03 | Compuestos antibacterianos. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20170007615A1 (es) |
EP (1) | EP3102203A2 (es) |
JP (1) | JP2017504662A (es) |
KR (1) | KR20160115986A (es) |
CN (1) | CN106170294A (es) |
AU (1) | AU2015212495A1 (es) |
BR (1) | BR112016018048A2 (es) |
CA (1) | CA2938459A1 (es) |
HK (1) | HK1232135A1 (es) |
IL (1) | IL247019A0 (es) |
MX (1) | MX2016010057A (es) |
PH (1) | PH12016501532A1 (es) |
SG (1) | SG11201606332PA (es) |
WO (1) | WO2015114452A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019057946A1 (en) | 2017-09-25 | 2019-03-28 | F. Hoffmann-La Roche Ag | MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS |
US11897859B1 (en) | 2023-03-09 | 2024-02-13 | King Faisal University | Coumarin compounds as antibacterial agents |
US11891362B1 (en) | 2023-04-14 | 2024-02-06 | King Faisal University | N2,N4-disubstituted pyrimidine-2,4-diamine compounds as antibacterial agents |
US11773084B1 (en) | 2023-04-14 | 2023-10-03 | King Faisal University | 4-arylamino-2-(6-indolylamino)pyrimidine compounds as antibacterial agents |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU782883B2 (en) | 2000-01-18 | 2005-09-08 | Vertex Pharmaceuticals Incorpoated | Gyrase inhibitors and uses thereof |
EP1251849A1 (en) | 2000-01-18 | 2002-10-30 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
BR0116216A (pt) | 2000-12-15 | 2004-08-17 | Vertex Pharma | Inibidores de girase e seus usos |
PL374191A1 (en) | 2002-06-13 | 2005-10-03 | Vertex Pharmaceuticals Incorporated | 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections |
AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
US7569591B2 (en) | 2003-01-31 | 2009-08-04 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
CN101321744A (zh) | 2005-11-07 | 2008-12-10 | 沃泰克斯药物股份有限公司 | 作为回旋酶抑制剂的苯并咪唑衍生物 |
GB0724349D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Antibacterial agents |
GB0612428D0 (en) | 2006-06-22 | 2006-08-02 | Prolysis Ltd | Antibacterial agents |
EP2018864A1 (en) * | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
KR20100095559A (ko) | 2007-11-07 | 2010-08-31 | 버텍스 파마슈티칼스 인코포레이티드 | 아미노벤즈이미다졸 우레아의 제조 방법 및 제조용 중간체 |
EP2229379A2 (en) | 2007-12-07 | 2010-09-22 | Vertex Pharmaceuticals Incorporated | Solid forms of 1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1h-benzo[d]imidazol-2-yl)urea |
GB0724342D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Anitbacterial compositions |
WO2011032050A2 (en) | 2009-09-11 | 2011-03-17 | Trius Therapeutics, Inc. | Gyrase inhibitors |
WO2012045124A1 (en) | 2010-10-08 | 2012-04-12 | Biota Europe Ltd | Bacteria topoisomerase ii inhibiting 2-ethylcarbamoylamino-1, 3-benzothiazol-5-yls |
BR112013017974B1 (pt) | 2011-01-14 | 2021-05-25 | Spero Therapeutics Inc. | inibidores de pirimidina girase e topoisomerase iv |
WO2012097270A1 (en) | 2011-01-14 | 2012-07-19 | Vertex Pharmaceuticals Incorporated | Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea |
SG191945A1 (en) | 2011-01-14 | 2013-08-30 | Vertex Pharma | Process of making gyrase and topoisomerase iv inhibitors |
ES2705923T3 (es) | 2011-01-14 | 2019-03-27 | Spero Trinem Inc | Formas sólidas de inhibidor de girasa (R)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1H-bencimidazol-2-il]urea |
KR20140059164A (ko) | 2011-03-15 | 2014-05-15 | 트라이우스 테라퓨틱스, 아이엔씨. | 트라이사이클릭 자이라제 억제제 |
JP5977344B2 (ja) * | 2011-06-20 | 2016-08-24 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ジャイレースおよびトポイソメラーゼ阻害剤のリン酸エステル |
WO2013091011A1 (en) * | 2011-12-21 | 2013-06-27 | Biota Europe Ltd | Heterocyclic urea compounds |
US8906902B2 (en) * | 2012-03-22 | 2014-12-09 | Biota Europe Limited | Antibacterial compounds |
WO2014014845A1 (en) | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases |
TWI595002B (zh) | 2012-07-18 | 2017-08-11 | 思沛羅三南公司 | (R)-2-(5-(2-(3-乙基脲基)-6-氟-7-(四氫呋喃-2-基)-1H-苯并[d]咪唑-5-基)嘧啶-2-基)丙烷-2-基磷酸二氫鹽之固體形式及其鹽 |
-
2015
- 2015-02-03 JP JP2016567168A patent/JP2017504662A/ja active Pending
- 2015-02-03 AU AU2015212495A patent/AU2015212495A1/en not_active Abandoned
- 2015-02-03 CN CN201580018631.9A patent/CN106170294A/zh active Pending
- 2015-02-03 MX MX2016010057A patent/MX2016010057A/es unknown
- 2015-02-03 BR BR112016018048A patent/BR112016018048A2/pt not_active Application Discontinuation
- 2015-02-03 WO PCT/IB2015/000177 patent/WO2015114452A2/en active Application Filing
- 2015-02-03 CA CA2938459A patent/CA2938459A1/en not_active Abandoned
- 2015-02-03 US US15/116,150 patent/US20170007615A1/en not_active Abandoned
- 2015-02-03 KR KR1020167024427A patent/KR20160115986A/ko not_active Application Discontinuation
- 2015-02-03 SG SG11201606332PA patent/SG11201606332PA/en unknown
- 2015-02-03 EP EP15708045.8A patent/EP3102203A2/en not_active Withdrawn
-
2016
- 2016-07-31 IL IL247019A patent/IL247019A0/en unknown
- 2016-08-03 PH PH12016501532A patent/PH12016501532A1/en unknown
-
2017
- 2017-06-09 HK HK17105756.4A patent/HK1232135A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN106170294A (zh) | 2016-11-30 |
BR112016018048A2 (pt) | 2017-08-08 |
WO2015114452A2 (en) | 2015-08-06 |
HK1232135A1 (zh) | 2018-01-05 |
IL247019A0 (en) | 2016-09-29 |
AU2015212495A1 (en) | 2016-08-18 |
KR20160115986A (ko) | 2016-10-06 |
PH12016501532A1 (en) | 2016-10-03 |
SG11201606332PA (en) | 2016-09-29 |
WO2015114452A3 (en) | 2015-11-12 |
EP3102203A2 (en) | 2016-12-14 |
CA2938459A1 (en) | 2015-08-06 |
JP2017504662A (ja) | 2017-02-09 |
US20170007615A1 (en) | 2017-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501577A1 (en) | Monobactam organic compounds for the treatment of bacterial infections | |
AU2019264537A1 (en) | Beta-lactamase inhibitors | |
PH12016502436A1 (en) | Anti-infective compounds | |
MY188541A (en) | Besifloxacin for the treatment of resistant acne | |
MX2018001075A (es) | Agentes terapeuticos y profilacticos antibacterianos. | |
NZ724798A (en) | Polymyxin derivatives as antimicrobial compounds | |
AU2012302022A8 (en) | Antibacterial compounds and methods for use | |
PH12017501019A1 (en) | Isoxazole hydromaxamic acid compounds as lpxc inhibitors | |
SG11201700621XA (en) | Antibiotic compositions for treating bacterial infections | |
PH12019500360A1 (en) | Antibiotic compounds | |
MX2018015125A (es) | Nuevos compuestos antibacterianos. | |
MX2016009248A (es) | Compuestos que contienen nitrogeno y su uso como agentes antibacterianos. | |
MX352760B (es) | Metodos para tratar infecciones intrapulmonares. | |
AU2015352440B2 (en) | Compounds | |
MX2017007371A (es) | Compuestos antibacterianos que tienen un amplio espectro de actividad. | |
MX2017009094A (es) | Derivado de polimixina y usos del mismo. | |
MX2017012073A (es) | Compuestos de minociclina para biodefensas. | |
MX2017007377A (es) | Compuestos organicos. | |
ZA202002093B (en) | Antibacterial compounds | |
PH12016501532A1 (en) | Antibacterial combinations comprising polymyxin | |
PH12018500358A1 (en) | Compounds for use in an antibacterial applications | |
IN2013MU03216A (es) | ||
EP3273797A4 (en) | Composition inhibiting gram-positive, pathogenic bacteria | |
PH12015500518A1 (en) | Tricyclic tetrahydroquinoline antibacterial agents | |
EP3212183A4 (en) | Synergistic compositions for treating microbial infections |